Mehl, J.; Akhoundova, D.; Bacher, U.; Jeker, B.; Rhyner Agocs, G.; Ruefer, A.; Soltermann, S.; Soekler, M.; Winkler, A.; Daskalakis, M.;
et al. Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers 2024, 16, 1854.
https://doi.org/10.3390/cancers16101854
AMA Style
Mehl J, Akhoundova D, Bacher U, Jeker B, Rhyner Agocs G, Ruefer A, Soltermann S, Soekler M, Winkler A, Daskalakis M,
et al. Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers. 2024; 16(10):1854.
https://doi.org/10.3390/cancers16101854
Chicago/Turabian Style
Mehl, Julian, Dilara Akhoundova, Ulrike Bacher, Barbara Jeker, Gaëlle Rhyner Agocs, Axel Ruefer, Susanne Soltermann, Martin Soekler, Annette Winkler, Michael Daskalakis,
and et al. 2024. "Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery" Cancers 16, no. 10: 1854.
https://doi.org/10.3390/cancers16101854
APA Style
Mehl, J., Akhoundova, D., Bacher, U., Jeker, B., Rhyner Agocs, G., Ruefer, A., Soltermann, S., Soekler, M., Winkler, A., Daskalakis, M., & Pabst, T.
(2024). Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery. Cancers, 16(10), 1854.
https://doi.org/10.3390/cancers16101854
